Pacemaker implantation (PMI) is a standard treatment for symptomatic bradyarrhythmia. Pneumothorax, aortic perforation, and pericardial effusion were reported as major complications of this procedure [1,2]. A cohort study in Denmark found that the incidence was 9.5% of 5918 patients who were implanted with a cardiac implantable electronic device (CIED), among which cardiac perforation was 0.6%, the male to female ratio was 1.1% vs 0.4% [2]. In the study of the recipients of permanent pacemakers from 2008 to 2012 in the USA, cardiac tamponade occurred in 2595 cases, which was 0.28% for the implantation of 922,549 patients [3]. Many cases can be managed conservatively with drainage or lead revision, but sometimes surgical intervention is required. We report a rare case of cardiac tamponade due to injury of the coronary artery by an atrial screw-in lead. Case reportA 74-year-old man visited the emergency room because of syncope. He was diagnosed with bradycardia tachycardia syndrome two years previously with presyncope. At that time, he took no drug that could cause bradycardia. Ambulatory electrocardiographic monitoring revealed maximum of 5 sec sinus arrest after the termination of atrial fibrillation, but he refused PMI. At
Background Transcatheter aortic valve replacement (TAVR) has emerged as an important therapeutic option among intermediate- and high-risk patients with symptomatic severe aortic stenosis. Heart rhythm disorders frequently complicate TAVR, particularly atrial fibrillation (AF), which can affect >40% patients undergoing the procedure. There is wide variation in rates of new-onset AF (NOAF) following TAVR across the initial pivotal randomized trials and observational studies, but burden of AF in each patient is not well known. The aim of this study is to evaluate AF burden detected by continuous patch ECG monitor (WR-100; Fukuda-Denshi, Tokyo,Japan) in patients after TAVR. Method Among KPUM-TAVR cohort, 58 consecutive patients (mean age:85.5±5.5, 44 females) kept recording continuous patch ECG monitor for 14 days after the procedure of TAVR. We excluded 11 patients with ECG indicating AF before procedure (paroxysmal AF 5, persistent AF 6). Finally, 47 eligible patients were selected according to the study criteria. AF was defined as a presence of AF more than 30sec on ECG monitor. The incidence and burden of NOAF was assessed. Results We identified 9 of 47 patients (19.1%) who developed NOAF (94% of transfemoral access patients, 6% of non- transfemoral access patients). Patients developing NOAF and had higher Society of Thoracic Surgeons risk scores (5.9±3.8 vs 9.9±6.3 p=0.0187). AF was first observed from day1 to day13. Despite having a median CHA2DS2-VASc score of 5 (25th and 75th percentile: 5 to 6), only 33% of patients with NOAF were given oral anticoagulation during the follow-up. Conclusion By using continuous patch ECG monitor, NOAF can be identified in 19.1% of patients after TAVR, with wide variety of first onset of AF. Given the clinical significance of post-TAVR AF, additional studies are necessary to describe the optimal management strategy in this high-risk population. Figure 1 Funding Acknowledgement Type of funding source: None
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.